Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489022 | 0.87 | LMNA (0.48) | LMNACHRM1TP53MEN1ALDH1A1 | |
| SCHEMBL2487513 | 0.84 | LMNA (0.84) | LMNACHRM1TP53CNR2 | |
| SCHEMBL9028399 | 0.81 | LMNA (1.00) | LMNACHRM1TP53CNR2 | |
| SCHEMBL31554247 | 0.81 | LMNA (1.00) | LMNACHRM1TP53CNR2 | |
| SCHEMBL18672281 | 0.81 | ALDH1A1 (0.56) | LMNAMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3234154 | 0.79 | LMNA (0.89) | LMNACHRM1TP53CNR2 | |
| SCHEMBL3228550 | 0.79 | LMNA (0.84) | LMNACHRM1TP53CNR2 | |
| SCHEMBL16341623 | 0.78 | LMNA (0.82) | LMNACHRM1TP53CNR2 | |
| SCHEMBL17943665 | 0.78 | ALDH1A1 (0.60) | LMNAMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL2487853 | 0.77 | CHRM1 (0.93) | LMNACHRM1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | claimed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | claimed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | claimed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178667-B2 | Benzyl-substituted quinolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2037739-B1 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME LLC | 2010-01-14 | — | — | US | disclosed |
| WO-2008002621-A2 | BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009962-A1 | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | CHRM1, OPRL1, MTNR1A | LMNA 3254/4885CHRM1 1/4885TP53 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.